Novo Nordisk A/S (NYSE:NVO) Stock Price Down 3.9% - Should You Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s stock price fell 3.9% on Friday . The company traded as low as $63.42 and last traded at $63.54. 8,898,081 shares changed hands during trading, an increase of 37% from the average session volume of 6,511,760 shares. The stock had previously closed at $66.15.

Analysts Set New Price Targets

A number of research firms recently weighed in on NVO. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $135.00.

Novo Nordisk A/S Price Performance

The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The company has a market cap of $288.05 billion, a PE ratio of 19.51, a PEG ratio of 0.90 and a beta of 0.65. The company's 50-day simple moving average is $67.59 and its 200 day simple moving average is $84.91.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The company had revenue of $11.87 billion during the quarter. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds and other institutional investors have recently modified their holdings of the company. Victory Capital Management Inc. raised its holdings in shares of Novo Nordisk A/S by 58.5% in the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after purchasing an additional 23,223 shares in the last quarter. Bryn Mawr Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Clear Creek Financial Management LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $450,000. DSM Capital Partners LLC raised its stake in Novo Nordisk A/S by 16.7% during the 4th quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock worth $172,678,000 after acquiring an additional 286,912 shares in the last quarter. Finally, Patrick M Sweeney & Associates Inc. raised its stake in Novo Nordisk A/S by 81.2% during the 4th quarter. Patrick M Sweeney & Associates Inc. now owns 11,155 shares of the company's stock worth $960,000 after acquiring an additional 5,000 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.